Skip to content

A registration study for the characteristics of coronary heart disease according to the Chinese medicine’s theory

A registration study for the characteristics of coronary heart disease according to the Chinese medicine’s theory

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ROC-17013221
Enrollment
Unknown
Registered
2017-11-02
Start date
2017-11-06
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary artery disease

Interventions

coronary artery disease group:nil

Sponsors

Guang'anmen Hospital, China Academy of Chinese Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Inpatients clinically suspected with CHD; (2) Plan to do the coronary angiography (CAG); (3) The age of participants is from 18 to 80; (4) Participants who voluntarily signed the informed consent.;Inclusion criteria: (1) Inpatients clinically suspected with CHD; (2) Plan to do the coronary angiography (CAG); (3) The age of participants is from 18 to 80; (4) Participants who voluntarily signed the informed consent.;Inclusion criteria: (1) Inpatients clinically suspected with CHD; (2) Plan to do the coronary angiography (CAG); (3) The age of participants is from 18 to 80; (4) Participants who voluntarily signed the informed consent.;Inclusion criteria: (1) Inpatients clinically suspected with CHD; (2) Plan to do the coronary angiography (CAG); (3) The age of participants is from 18 to 80; (4) Participants who voluntarily signed the informed consent.;Inclusion criteria: (1) Inpatients clinically suspected with CHD; (2) Plan to do the coronary angiography (CAG); (3) The age of participants is from 18 to 80; (4) Participants who voluntarily signed the informed consent.

Exclusion criteria

Exclusion criteria: (1) Participants with acute infection, trauma, burns, surgical history in latest one week; (2) Participants have already received PCI or CABG, or have received other vascular(including: cardio-cerebral vascular and peripheral vascular) interventional treatment; (3) Uncontrolled hypertension (occasional rest blood pressure higher than 160/100mmHg in one week, under drug control), severe ventricular arrhythmia, degree III atrioventricular block; (4) Other heart disease, such as: rheumatic heart disease, pulmonary heart disease, hyperthyroidism heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy, severe valvular disease, myocarditis, pericarditis; (5) Participants with aortic dissection, aortic aneurysms, pulmonary embolism and severe myocardial bridge; (6) Participants with acute exacerbation of chronic obstructive pulmonary disease and respiratory failure; (7) Participants with liver dysfunction, alanine aminotransferase(ALT)>3 times the normal value, or combined with cirrhosis; with kidney dysfunction, estimated glomerular filtration rate (eGFR)3 times the normal value, or combined with cirrhosis; with kidney dysfunction, estimated glomerular filtration rate (eGFR)3 times the normal value, or combined with cirrhosis; with kidney dysfunction, estimated glomerular filtration rate (eGFR)3 times the normal value, or combined with cirrhosis; with kidney dysfunction, estimated glomerular filtration rate (eGFR)3 times the normal value, or combined with cirrhosis; with kidney dysfunction, estimated glomerular filtration rate (eGFR)<30mL/min/1.73m2; (8) Participants with hematopoietic system disease, malignant tumor, autoimmune disorders and infectious disease(tuberculosis, viral hepatitis, syphilis and acquired immune deficiency syndrome); (9) Participants with acute cerebral stroke, severe complications of diabetes(diabetic foot, diabetic ketoacidosis); (10) Participants with organ transplantation; (11) Participants with psychosis or dysgnosia; (12) Pregnant or lactating women; (13) Refusing to sign the informed consent.

Design outcomes

Primary

MeasureTime frame
Demographic data;General clinical data;Four Diagnosis of TCM;Coronary angiography;

Secondary

MeasureTime frame
Blood routine examination;Blood biochemical examination;Coagulation index;BNP;Myocardial enzyme;Ultrasonic cardiogram;Electrocardiograph;GRACE risk score;

Countries

China

Contacts

Public ContactJie Wang;Jie Wang;Jie Wang;Jie Wang;Jie Wang ;;;;

Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences;Guang'anmen Hospital, China Academy of Chinese Medical Sciences

wangjie0103@126.com;wangjie0103@126.com;wangjie0103@126.com;wangjie0103@126.com;wangjie0103@126.com+86 010-88001817;+86 010-88001817;+86 010-88001817;+86 010-88001817;+86 010-88001817

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 25, 2026